Virpax Pharmaceuticals IncNASDAQ:VRPXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5024
- TODAY'S CHANGE (%)0.0053 (1.0662%)
- Bid / Lots0.4971/ 2
- Ask / Lots0.5199/ 9
- Open / Previous Close0.5191 / 0.4971
- Day Range
- 52 Week Range
- Volume21,869
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRPX |
|---|---|---|
| 09:41 ET | 100 | 0.5191 |
| 09:50 ET | 100 | 0.52 |
| 10:06 ET | 1600 | 0.5 |
| 10:10 ET | 350 | 0.502 |
| 10:15 ET | 590 | 0.502101 |
| 10:28 ET | 561 | 0.52005 |
| 10:51 ET | 100 | 0.5111 |
| 11:00 ET | 200 | 0.5111 |
| 11:31 ET | 581 | 0.536899 |
| 12:03 ET | 7902 | 0.5022 |
| 12:38 ET | 252 | 0.5022 |
| 03:20 ET | 500 | 0.5111 |
| 03:21 ET | 475 | 0.52 |
| 03:43 ET | 200 | 0.519 |
| 03:52 ET | 1900 | 0.5021 |
| 03:59 ET | 5006 | 0.5024 |
May 29, 2024
Virpax(R) Pharmaceuticals to Present at 2024 BIO International Convention, from 7:30AM ET on Wednesday May 29, 2024 by Dow Jones
7:30AM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Virpax Pharmaceuticals Inc | 1.4M | 0.0x | --- |
eFFECTOR Therapeutics Inc | 1.3M | 0.0x | --- |
GRI Bio Inc | 1.4M | 0.0x | --- |
CohBar Inc | 1.5M | -0.1x | --- |
Agentix Corp | 1.4M | -1.4x | --- |
180 Life Sciences Corp | 1.4M | 0.0x | --- |
Company Information
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
Contact Information
- Headquarters
- 1055 Westlakes Drive, Suite 300BERWYN, PA, United States 19312
- Phone
- 610-727-4597
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Eric Floyd
- Chief Executive Officer, Executive Vice President, Commercial Operations Officer, Director
- Gerald Bruce
- Chief Financial Officer
- Vinay Shah
- Independent Director
- Michael Dubin
- Independent Director
- Thani Jambulingam
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.16 |
EPS | $-14.42 |
Book Value | $1.65 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
